EQT Life Sciences has led an $80 million Series A funding round in Mosanna Therapeutics, aiming to advance their nasal spray for sleep apnea treatment through Phase 2 Clinical Trials.

Jun 09, 2025•6 months ago

Amount Raised

$80 Million

Redwood CityBiotechnology

Investors

High Tech Gründerfonds (Htgf)Supermoon CapitalForty51 VenturesNorwestBroadview VenturesForbionPivotal Bio Venture PartnersEqt Life Sciences

Description

Mosanna Therapeutics raises $80 million in a Series A funding round to develop its nasal spray therapy for obstructive sleep apnea. The financing was led by EQT Life Sciences and Pivotal bioVenture Partners, with contributions from several co-lead investors. David Weber has been appointed as CEO to steer the company through clinical development. The company is based in Basel, Switzerland.

Company Information

Company

Mosanna Therapeutics

Location

Redwood City, California, United States

About

Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body's natural airway control during sleep, Mosanna's lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends